Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ASTH
ASTH logo

ASTH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Astrana Health Inc (ASTH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
39.170
1 Day change
2.65%
52 Week Range
40.130
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Astrana Health Inc (ASTH) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has shown consistent positive momentum, bullish moving averages, and strong analyst upgrades with increasing price targets. Despite the lack of recent news or financial data, the overall sentiment and technical indicators support a buy decision.

Technical Analysis

The stock is showing bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating a positive trend. The RSI is neutral at 62.507, and the MACD histogram is slightly negative (-0.167) but contracting, suggesting potential stabilization. Key resistance levels are at 39.82 and 40.796, with support at 38.24 and 36.661. The current price of $39.17 is above the pivot point of $38.24, reinforcing the bullish trend.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
11

Positive Catalysts

  • Multiple analyst upgrades with price targets raised significantly (e.g., Barclays to $50, Truist to $47, TD Cowen to $45).

  • Positive outlook on value-based care and stabilizing cost trends.

  • Bullish technical indicators and price momentum.

Neutral/Negative Catalysts

  • Lack of recent news or event-driven catalysts.

  • No significant trading trends from hedge funds or insiders.

  • Slightly negative MACD histogram, though contracting.

Financial Performance

No financial data available for analysis. However, analysts have cited strong Q1 earnings and better-than-expected results as reasons for their upgrades.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are highly positive on Astrana Health, with multiple upgrades and raised price targets. Barclays upgraded the stock to Overweight with a $50 target, citing improved outlooks for value-based care and Medicare Advantage rates. Other firms, including Truist and TD Cowen, have also raised their targets, reflecting strong confidence in the company's growth and integration efforts.

Wall Street analysts forecast ASTH stock price to fall
8 Analyst Rating
Wall Street analysts forecast ASTH stock price to fall
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 38.160
sliders
Low
26
Averages
33.2
High
40
Current: 38.160
sliders
Low
26
Averages
33.2
High
40
Barclays
Equal Weight
to
Overweight
upgrade
$37 -> $50
AI Analysis
2026-05-26
Reason
Barclays
Price Target
$37 -> $50
AI Analysis
2026-05-26
upgrade
Equal Weight
to
Overweight
Reason
Barclays upgraded Astrana Health to Overweight from Equal Weight with a price target of $50, up from $37. The firm says the outlook for value-based care has \"materially improved in recent weeks driven by encouraging signs\" of stabilizing cost trends and a more favorable 2027 Medicare Advantage rate outcome. Astrana has room for multiple expansion as its executes on its integration of Prospect and accelerates full-risk membership growth, the analyst tells investors in a research note.
Truist
Buy
maintain
$38 -> $47
2026-05-14
Reason
Truist
Price Target
$38 -> $47
2026-05-14
maintain
Buy
Reason
Truist raised the firm's price target on Astrana Health to $47 from $38 and keeps a Buy rating on the shares. The firm is citing the company's Q1 earnings beat while also noting that its higher valuation target - enterprise value to expected EBITDA at 11-times vs.10-times prior - reflects its incremental positivity in Astrana's integration of Prospect, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ASTH
Unlock Now

People Also Watch